

Market Round-up

V27 – 30th November, 2018

General Market News:

- New research from **Roche UK** has revealed that 82% of Generation Z (16-24 year olds) want to see the NHS introduce digital solutions to better manage their health and improve care.
[LINK](#)
- The NHS is set to save a record £300 million after negotiating deals with five manufacturers on low-cost versions of the health service's most costly drug - **AbbVie's Humira**
[LINK](#)
- First children set to receive **Novartis' Kymriah** in UK
[LINK](#)
- The FDA has granted **Pfizer's Lyrica** (pregabalin), and extension of 6 months US market exclusivity
[LINK](#)
- Bayer AG says it's cutting 12,000 jobs worldwide as it seeks to reduce costs.
[LINK](#)
- **MSD** raised prices on five drugs including Keytruda in November
[LINK](#)
- **Novo Nordisk** launches type II diabetes awareness campaign
[LINK](#)
- **Vertex** announces Cystic Fibrosis data to take it to the finish line
[LINK](#)
- **Vodafone** teams with **HealthBeacon** for patient medication tool
[LINK](#)

NCPE Drug Updates

- No updates.

Brexit:

- **Ibec** have launched a Brexit Tracker providing a summary of the key issues for business and an update on the state of play.
[LINK](#)
- The government's Brexit deal will leave the UK £100bn worse off a year than if it had remained in the EU, a study by the National Institute of Economic and Social Research has said.
[LINK](#)
- Sibby Buckle Vice Chair of the **Royal Pharmaceutical Society English Pharmacy Board** has suggested that UK Pharmacists be enabled to make therapeutic switches before Brexit
[LINK](#)

Biologics / Biosimilars:

- The EC have approved **Mundipharma's** use of **Pelmeg**, a biosimilar of **Amgen's** white blood cell booster **Neulasta**.
[LINK](#)
- **Amgen** withdraws its membership from the **Biosimilars Forum** – which it was a founding member of
[LINK](#)

Drug Approvals/Filings:

- Regulators in Europe have approved **Novartis's Luxturna** to treat a rare inherited condition that causes sight loss.
[LINK](#)
- The EC have approved **Mundipharma's** use of **Pelmeg**, a biosimilar of **Amgen's** white blood cell booster **Neulasta**.
[LINK](#)
- **MSD** received approval for 2 HIV medicines in EU - **Pifeltro** and **Delstrigo**
[LINK](#)
- **Astellas** scores first US blood cancer approval with **Xospata**
[LINK](#)
- The European Commission has approved **Novartis's Gilenya** (fingolimod) for the treatment of children and adolescents 10 to 17 years old with relapsing-remitting forms of **multiple sclerosis** or RRMS.
[LINK](#)

Further Reading:

- *White Paper: Migraine Treatment and Calcitonin Gene-Related Peptide Inhibitors: A Real-World Electronic Health Record Case Study.*
[LINK](#)
 - Four things I've learned after 18 months as **Actelion** Global Head – **Jane Griffiths**
[LINK](#)
-